Overview
FDMT market data
Price History
FDMT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.73 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -182.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.46 – $14.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $609M · P/B 0.85 · P/S 6.90.
Company News
4D Molecular Therapeutics Q2 EPS $(1.04) Beats $(1.06) Estimate, Sales $3.781M Beat $3.100M EstimateBenzinga · Aug 13, 2026, 8:24 PM
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37Benzinga · Jul 31, 2026, 3:52 PM
4D Molecular's One-Shot Eye Therapy Delivers Two-Year WinBenzinga · Jul 20, 2026, 1:05 PM
8-K filing — 4D Molecular Therapeutics, Inc. (FDMT)SEC EDGAR · Jul 20, 2026, 12:30 PM
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price TargetBenzinga · Jul 20, 2026, 10:57 AM
Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration SubgroupBenzinga · Jul 20, 2026, 6:54 AM
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalGlobenewswire Inc · Jun 29, 2026, 12:15 PM
4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular DegenerationBenzinga · Jun 29, 2026, 12:05 PM
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · Jun 18, 2026, 5:15 PM